Combination therapy of DPP-4 inhibitor and metformin: Rationality and its evidence

Ye LIU,Tian-pei HONG
DOI: https://doi.org/10.3760/cma.j.issn.1000-6699.2012.12.022
2012-01-01
Abstract:Metformin improves glycemic control mainly due to improved insulin sensitivity.Dipeptidyl peptidase-4(DPP-4) inhibitor,which suppresses degradation of glucagon-like peptide-1 (GLP-1) and maintains the bioactivity of endogenous GLP-1,improves islet dysfunction.Moreover,recent studies suggested that metformin enhanced the biological effect of GLP-1 via different mechanisms and that DPP-4 inhibitor enhanced insulin sensitivity in type 2 diabetes.Therefore,the combination therapy of DPP-4 inhibitor and metformin could simultaneously ameliorate the two major defects of type 2 diabetes and obtain complementary and synergistic benefits for glycemic control.
What problem does this paper attempt to address?